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Abstract
Rationale: Primary graft dysfunction (PGD) is a form of acute lung
injury that occurs after lung transplantation. The deﬁnition of PGD
was standardized in 2005. Since that time, clinical practice has
evolved, and this deﬁnition is increasingly used as a primary endpoint
for clinical trials; therefore, validation is warranted.
Objectives:We sought to determine whether reﬁnements to
the 2005 consensus deﬁnition could further improve construct
validity.
Methods: Data from the Lung Transplant Outcomes Group
multicenter cohort were used to compare variations on the
PGD deﬁnition, including alternate oxygenation thresholds,
inclusion of additional severity groups, and effects of procedure
type and mechanical ventilation. Convergent and divergent validity
were compared for mortality prediction and concurrent lung injury
biomarker discrimination.
Measurements and Main Results: A total of 1,179 subjects
from 10 centers were enrolled from 2007 to 2012. Median length of
follow-up was 4 years (interquartile range = 2.4–5.9). No mortality
differences were noted between no PGD (grade 0) and mild PGD
(grade 1). Signiﬁcantly better mortality discrimination was evident
for all deﬁnitions using later time points (48, 72, or 48–72 hours;
P, 0.001). Biomarker divergent discrimination was superior when
collapsing grades 0 and 1. Additional severity grades, use of
mechanical ventilation, and transplant procedure type had minimal
or no effect on mortality or biomarker discrimination.
Conclusions: The PGD consensus deﬁnition can be simpliﬁed by
combining lower PGD grades. Construct validity of grading was
present regardless of transplant procedure type or use of mechanical
ventilation. Additional severity categories had minimal impact on
mortality or biomarker discrimination.
Keywords: lung transplant; primary graft dysfunction; lung
transplant outcomes
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Primary graft dysfunction (PGD) is a form
of acute respiratory distress syndrome
(ARDS) developing during the immediate
postoperative period after lung
transplantation. PGD signiﬁcantly
contributes to increased short-term
mortality and morbidity (1–5). Patients who
develop PGD also show signiﬁcantly worse
long-term outcomes (1, 3, 6, 7). The
currently employed four-tiered PGD
grading system was developed in 2005 by
the ISHLT (International Society for Heart
and Lung Transplantation) Working
Group, and is currently under
reconsideration by an updated ISHLT
Working Group (8–12). At the time of
publication in 2005, the ISHLT Working
Group noted the importance of construct
validity in a PGD consensus deﬁnition, and
called for appropriate future deﬁnition
reﬁnements (13).
The original ISHLT PGD deﬁnition
paralleled the AECC (American–European
Consensus Conference) deﬁnition of ARDS (14).
The “Berlin” deﬁnition, a recent
reﬁnement to the AECC ARDS deﬁnition,
was developed to address the limitations of
acuity assessments, effects of ventilator
settings on oxygenation, and difﬁculties
with interpretation of chest radiographs
that emerged over the subsequent 18 years
since its standardization (15). Similar
concerns have emerged with the ISHLT
PGD deﬁnition; over the past 12 years,
multiple suggestions for alterations to the
PGD grading system have been made,
including modiﬁcations to the PaO2/FIO2
(P/F) cutoffs, optimal timing of grading,
effects of mechanical ventilation, including
positive end-expiratory pressure, as well
as differences according to transplant
procedure type (13, 16–22). In addition,
although the 2005 deﬁnition has been used
to enhance understanding of PGD risks,
mechanisms, and development of new
therapies, practice has changed since that
time, whereas the updated 2017 ISHLT
deﬁnition has remained relatively
unchanged (23, 24). In recent years, PGD
has been considered as the primary
outcome by governing bodies as a response
indicator variable for new therapies aimed
at improving lung transplant outcomes
(23, 25).
The goal of this study was to establish
the validity of PGD grading in the
post–Lung Allocation Score era, to consider
reﬁnements to the deﬁnition based
on differing thresholds of oxygenation,
and to determine the effects of procedure
type and use of mechanical ventilation on
PGD grade. As there is no “gold standard”
for PGD, we used convergent and
P/F ratio ≥ 300
– CXR
≥ 300
+ CXR
299–200
+ CXR
199–100
+ CXR
<100
+ CXR
ISHLT No PGD
Grade 0
No PGD
Grade 0/1
No PGD
Grade 0/1
Mild
Grade 1
Moderate
Grade 2
Moderate
Grade 2
Moderate
Grade 2
Severe
Grade 3
Severe
Grade 3
Severe
Grade 3
Very Severe
Grade 4
Revised
Berlin
Figure 1. Definition of primary graft dysfunction (PGD). Depicted are the PaO2/FIO2 (P/F) thresholds for
the three variations of the definitions tested. CXR = chest X-ray; ISHLT = International Society for
Heart and Lung Transplantation.
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At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: The International Society for
Heart and Lung Transplantation
(ISHLT) consensus deﬁnition
developed in 2005 has been
instrumental in enhancing the
transplant community’s ability to
study and understand primary graft
dysfunction (PGD) after lung
transplantation. Since that time,
questions have arisen about how best
to improve the deﬁnition to ensure
adequate construct validity with
respect to timing of grading, oxygen
exchange cutoffs, transplant type, and
use of mechanical ventilation.
What This Study Adds to the
Field: We tested the construct
validity of varying PGD deﬁnitions
for mortality and biomarker
discrimination using a multicenter,
prospective cohort study collected and
curated by the Lung Transplant
Outcomes Group. We determined that
the 2005/2017 ISHLT consensus
deﬁnition can be simpliﬁed by
combining lower PGD grades. In
addition, construct validity of grading
was maintained, regardless of
transplant procedure type or use
of mechanical ventilation. Lastly,
additional higher severity categories
had minimal impact on mortality or
biomarker discrimination.
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divergent validity techniques, focusing on
mortality discrimination and established
lung injury biomarkers. Some of the results
of these studies have been previously
reported in the form of an abstract (26).
Methods
Study Populations and Design
Subjects were selected from the LTOG
(Lung Transplant Outcomes Group) cohort,
which is a multicenter prospective cohort
study of lung transplant recipients designed
to study PGD and its outcomes
(NCT00457847) (24). Institutional review
board approval and written informed
consent were obtained before the
recruitment of subjects. We tested the
construct that mortality and lung injury
biomarkers would diverge or converge for
different PGD grades (divergent and
convergent validity). Two distinct
populations were deﬁned from this cohort
to address divergent validity separately for
mortality and for lung injury biomarkers, as
not all subjects had biomarkers measured.
The ﬁrst population used to assess
mortality discrimination was composed of
consecutive subjects transplanted between
2007 and 2012 from 10 centers who had
PGD grading at each time point (0, 24, 48,
and 72 h) with follow-up until March 2017
(see Figure E1 in the online supplement).
The second group was composed of
consecutive subjects transplanted between
2002 and 2006 from six centers with
available biomarker data, which were used
to gauge convergent and discriminant
validity between PGD deﬁnitions (27).
Clinical data were collected prospectively,
as previously described (24). Multiple organ
transplant and retransplant recipients were
excluded (Figure E1).
Deﬁnitions
We used the ISHLT consensus deﬁnition of
PGD (8) and considered alternative
deﬁnitions based on P/F ratio (Figure 1).
Primarily, we tested combining lower
grades (P/F. 300) precluding the need for
chest radiograph assessments, as well as
adding additional severe grades (P/F,
100), and determining the effects of
presence or absence of mechanical
ventilation, transplant procedure type, and
timing of grading (additional detail on
deﬁnitions provided in the online
supplement).
PGD Biomarkers
In previous studies, several biomarkers have
been reported to be associated with PGD
(28–32). Of the reported biomarkers,
plasminogen activator inhibitor (PAI)-1
was found to be the most strongly
associated with severe PGD, and was
thus chosen as our primary marker for
discrimination (27). Plasma samples
were prospectively collected 24 hours
after transplantation in a subset of
LTOG participants between 2002 and
2006. Samples were centrifuged within
60 minutes and then stored at 2808C for
subsequent analysis, and plasma levels of
PAI-1 were determined using commercially
available ELISAs, as previously described
(27, 33).
Statistical Analysis
The predictive (discriminant) validity for
30-day mortality of each deﬁnition was
compared with receiver operating curve
analysis in logistic regression models using
Table 1. Demographics
Overall Population (n = 1,179)
Donor
Age, mean (SD), yr 34.8 (14.1)
Female, % 36.6
Ethnicity, %
Caucasian 60.3
African American 23.5
Hispanic 13.1
Other 3.1
Ventilatory support, mean (SD), d 3.1 (2.3)
PaO2, mean (SD), mm Hg 492 (77.2)
Smoking history, % 30.2
BMI, mean (SD), kg/m2 26.1 (5.8)
Mode of death, %
Blunt trauma 4.3
Head trauma 37.8
Stroke 36.6
Anoxia 13.2
Other 8.0
Recipient
Age, mean (SD), yr 54.7 (13.3)
Female, % 42.0
Ethnicity, %
Caucasian 86.3
African American 8.5
Hispanic 3.1
Other 2.2
BMI, mean (SD), kg/m2 25.0 (4.8)
Diagnosis, %
COPD 34.1
Idiopathic pulmonary ﬁbrosis 40.0
Cystic ﬁbrosis 14.3
Pulmonary arterial hypertension 3.2
Other 8.4
Lung allocation score 44.8 (14.9)
Operative
Transplant type, %
Single 29.6
Bilateral 70.4
CPB used, % 36.2
CPB time, mean (SD), min 220.9 (81.4)
Intraoperative nitric oxide, % 44.7
Total ischemic time, mean (SD), min 333.4 (103.8)
Outcomes
Mechanical ventilation, mean (SD), d 4.1 (18.0)
Ventilator-free days, mean (SD) 25.7 (18.1)
Hospital length of stay, mean (SD), d 23.3 (24.9)
Total survival, mean (SD), d 1,098.8 (619.9)
Definition of abbreviations: BMI = body mass index; COPD = chronic obstructive pulmonary disease;
CPB = cardiopulmonary bypass.
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dummy variables for deﬁned PGD
categories based on P/F variation (34).
Discrimination of overall survival between
the different grades was assessed using
Kaplan-Meier and multivariable Cox
proportional hazard methods, also
employing grades as dummy variables.
Models were ﬁt using potential
confounding variables previously associated
with PGD and/or mortality (donor
smoking history, recipient diagnosis,
recipient body mass index, recipient
pulmonary artery pressure, transplant type,
cardiopulmonary bypass use, and recipient
reperfusion FIO2) (24, 35, 36). Analyses of
effects of interval timing, transplant type,
and mechanical ventilator status on
discrimination were similarly compared
using logistic regression and receiver
operating curve comparison using the
“roccomp” and “rocgold” commands in
STATA v12.1 software (STATA Corp.)
(37). Tests for interaction between
transplant type, ventilator status, and PGD
grade on mortality were performed using
multiplicative interaction terms in the
regression framework. Center effects were
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Figure 2. Risk of 30-day and 5-year mortality. Summarized in the left-most panels are the odds ratio point estimates and 95% confidence intervals (CIs)
for 30-day mortality obtained from logistic regression for each definition at the 48- to 72-hour intervals for the (A) International Society for Heart and Lung
Transplantation (ISHLT), (C) revised, and (E) Berlin-type definitions. The asterisk denotes significant increase of overall mortality in Cox models adjusted for
donor smoking history, recipient diagnosis, body mass index, pulmonary artery pressure, transplant type, cardiopulmonary bypass use, and reperfusion
FIO2. In the right-most panels, Kaplan-Meier survival curves demonstrate unadjusted 5-year survival for the (B) ISHLT, (D) revised, and (F) Berlin-type
definitions.
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evaluated using conditional logistic
regression. One-way ANOVA was used for
comparison of biomarker concentrations
at 24 hours between each grade. In all
analyses, a two-sided P value of 0.05 was
considered statistically signiﬁcant.
Results
Characteristics of Mortality
Discrimination Cohort
A total of 1,179 subjects was included from
the LTOG cohort, had PGD grading at each
time point (0, 24, 48, and 72 h), and were
evaluated for mortality discrimination.
Demographics of this cohort are presented
in Table 1. Follow-up was completed in
1,179 subjects (100%) with a median length
of follow-up of 4 years (interquartile range =
2.4–5.9). Survival at 90 days, 6 months, and
1, 3, and 5 years was 94%, 92%, 88%, 72%,
and 66%, respectively (Figure E2).
The incidence of PGD severity by P/F
ratio at discrete time points and during
speciﬁed intervals is displayed in Figure E3.
There was decreasing incidence of higher-
grade PGD with grading at later time points.
As a consequence, the proportion of
transplanted patients with a P/F ratio
greater than 300 steadily increased with time
after transplant, and was greater than 0.8 by
the 72-hour time point. Speciﬁc incidences
of PGD using the 72-hour, 0- to 72-hour, or
48- to 72-hour time points are available in
Table E2.
Mortality Discrimination by Deﬁnition
The mortalities by grade using the standard
ISHLT, revised, and Berlin-type
modiﬁcations based on P/F ratio thresholds
were compared. Under the ISHLT
deﬁnition, mild PGD (P/F. 300 with
abnormal chest radiograph) had no
signiﬁcant 30-day mortality difference from
no PGD (P/F. 300 with normal chest
radiograph, P = 0.51; Figure 2a) using the
most common interval grading (0–72 h) or
at any other individual time point or other
interval (P values ranged between 0.14 at
time (T) 0 to 0.91 at T72; see Tables
E3–E7). Conditional logistic regression
demonstrated nearly identical point
estimates and signiﬁcance, indicating
minimal center effects (Table E8). Kaplan-
Meier analysis displayed no differences
between no and mild PGD with
overlapping survival curves (log-rank
P = 0.70; Figure 2B).
At almost all discrete time points or
combined intervals, the revised deﬁnition
with combined grades of P/F greater than
300 demonstrated better stratiﬁed mortality
risk based on PGD severity (Figure 2C).
Longer-term mortality risk (90 d and 1 yr)
also demonstrated good risk stratiﬁcation
using this deﬁnition (log-rank P, 0.0001;
Figure 2D). The Berlin-type deﬁnition
signiﬁcantly improved stratiﬁed mortality
risk based on addition of a very severe
category (Figure 2E). However, there was
overlap without differential longer-term
mortality risk between the severe and
very severe groups (log-rank P = 0.93;
Figure 2F), indicating that any beneﬁt from
addition of a very severe category was
limited to early mortality.
Comparisons of the ISHLT, revised, and
Berlin-type deﬁnitions also demonstrated
signiﬁcant improvement in discriminant
validity using later discrete (48 or 72 h;
Figures E4–E6) or interval (48–72 h; Figures
E4–E6) time points (Table 2). Despite
superior performance with later grading,
early risk stratiﬁcation (0 h) was possible
among all deﬁnitions. However, earlier
grading time points attenuated discriminant
validity for ISHLT (area under the curve
[AUC] = 0.65), revised (AUC = 0.68), and
Berlin-type (AUC = 0.68) deﬁnitions.
A multivariable Cox proportional
hazards model was ﬁt using potentially
confounding variables previously associated
with PGD and/or mortality (24, 35).
Common to all deﬁnitions was an
approximately twofold increase in risk of
mortality for severe PGD grades after
adjustment. Of note, the Berlin-type very
severe stratum did not appreciably differ
from the severe category, with a similar
twofold increased risk of mortality (Table
E9), indicating little effect of addition of
this severity group on long-term mortality.
Divergent Discrimination of Known
Lung Injury Biomarkers
Based on prior publications (27–29), we
chose a known lung injury biomarker with
the strongest association with PGD to test
divergent discrimination with the different
PGD deﬁnitions. PAI-1 plasma levels for
each grade, by deﬁnition, from 315
recipients are depicted in Figure 3. There
was no signiﬁcant difference in PAI-1
plasma level between no PGD and mild
PGD (P = 0.99), concordant with our
demonstrated lack of mortality risk
difference between these grades. Plasma
PAI-1 levels demonstrated signiﬁcant
incremental elevation with moderate
(ISHLT, P = 0.04; revised, P = 0.03; Berlin-
type, P = 0.055) and severe grades of PGD
(ISHLT, P = 0.001; revised, P, 0.001;
Berlin-type, P, 0.001), but not for very
severe grades (P = 0.14). Sensitivity analyses
using nonparametric methods also
conﬁrmed these observations.
Effects of Ventilator Status and
Transplant Procedure Type
on Deﬁnitions
To evaluate the effects of ventilator status on
deﬁnitions, all non-mechanically ventilated
patients were recoded to have no PGD
(grade 0), as has been previously suggested
(18, 20). Noninvasive ventilation was only
used in four patients during the ﬁrst 3 days
Table 2. Construct Discriminant Validity across Grading Assumptions
ISHLT Revised Berlin-Type
AUC P Value AUC P Value AUC P Value
Timing
0–72 h 0.685 — 0.679 — 0.708 —
48–72 h 0.755 0.002 0.744 0.008 0.749 0.103
Ventilator status
Ventilation 0.755 — 0.744 — 0.749 —
No ventilation 0.747 0.770 0.743 0.941 0.751 0.727
Transplant type
Single-lung Tx 0.841 — 0.814 — 0.811 —
Bilateral-lung Tx 0.717 0.118 0.713 0.261 0.720 0.319
Definition of abbreviations: AUC = area under the curve; ISHLT = International Society for Heart and
Lung Transplantation; Tx = transplant.
Comparisons of significance within definitions are listed directly to the right of the AUC. There were no
significant differences in discriminant ability between definitions for each assumption. Note: single and bilateral
cohorts are abstracted from the 48- to 72-hour interval definitions, and the significance is determined using a
chi-square test of the receiver operating characteristic curves comparing single to bilateral.
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in this cohort, and was thus treated
similarly to mechanical forms of
ventilation. The resulting model showed no
signiﬁcant loss of discrimination (Table 2).
Among all deﬁnitions with varying P/F
thresholds, results were similar regardless
of presence or absence of mechanical
ventilation. In addition, we were unable to
demonstrate any interaction of ventilator
status and 30-day mortality. Further
sensitivity analysis using less extreme
variations of deﬁnition determined by
inﬁltrates on chest radiograph (no
inﬁltrates, no PGD: grade 0; inﬁltrates, mild
PGD: grade 1) similarly had little effects on
mortality discrimination.
Because the decision to continue or
discontinue mechanical ventilation can
potentially affect PGD grading, particularly
when used at 72 hours as an endpoint for
unblinded clinical trials, further analysis of the
severe PGD groups was conducted. Among
those in the 72-hour severe PGD (grade 3)
group who were reclassiﬁed as no PGD (grade
0) due to not receiving mechanical ventilation,
the 30-day mortality risk appeared to be
intermediate when compared with those
receiving mechanical ventilation: 7% for
nonmechanically ventilated reclassiﬁed versus
14% for mechanically ventilated severe PGD
(P = 0.32) and versus 1% for no PGD (P =
0.03), as displayed in Figure 4.
With respect to transplant procedure
type, incremental risk per grade was
consistent across all deﬁnitions within both
single and bilateral lung transplants. We
were unable to demonstrate an interaction
between transplant type with PGD grade for
any deﬁnition (P = 0.09–0.88). Likewise,
discrimination was not signiﬁcantly
different between single or bilateral
transplants, despite a nominally higher
AUC for mortality discrimination within
single-lung transplants (Table 2).
Discussion
The ISHLT consensus deﬁnition of 2005
has been instrumental in enhancing the
transplant community’s ability to study
and understand the incidence, related
outcomes, risk factors, biomarkers, and
genomic factors inﬂuencing PGD.
However, clinical practice has changed,
and clinical trials are now being conducted
with increasing frequency using PGD as
the outcome for approval by governing
bodies (22, 24). Thus, a valid PGD grading
method is essential in objectively assessing
the risks and beneﬁts of a therapy. In this
study, we have shown that deﬁnitions
combining categories with P/F greater than
300 improve convergent and discriminant
validity in the context of associated
biomarkers and mortality compared with
the existing deﬁnition. Furthermore, the
addition of more severe categories did not
enhance the deﬁnition, except at the earliest
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Figure 3. Plasminogen activator inhibitor (PAI)-1 biomarker association with primary graft dysfunction
(PGD) definitions. Displayed are comparisons of PGD grade assessed between 48 and 72 hours for
(A) International Society for Heart and Lung Transplantation, (B) revised, and (C) Berlin-type definitions.
In this box-and-whisker plot, the box defines the upper/lower quartiles, the line depicts the median,
and the whiskers the maximum and minimum values. Significance was determined using ANOVA.
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grading times. We have also demonstrated
that later time points for assessment of
PGD grade (48–72 h) have better
discrimination for mortality, and all
grading constructs based on P/F ratios
perform well, regardless of transplant type
or mechanical ventilation status.
With respect to 30-day, 90-day and
1-year mortality, there were no signiﬁcant
differences in risk between no (grade 0)
and mild (grade 1) PGD at any time point
or interval. Differences between these
categories are determined by ﬁndings on chest
radiography; thus, for grades with P/F ratios
over 300 mm Hg, there was no difference in
mortality, regardless of chest radiograph
results. Biomarker data likewise demonstrated
no signiﬁcant differences in plasma levels of
PAI-1 between no PGD and mild PGD.
Furthermore, addition of a very severe PGD
category did not reduce discriminant ability of
30-day mortality, did not enhance biomarker
discriminant validity, and demonstrated
similar overall mortality risk as severe PGD.
There was improved mortality and
biomarker discrimination when grading
was employed at later time points. It is
reasonable to recommend that PGD
prevention and risk studies focus on 48- to
72-hour grading time points, given the
demonstrated superior discriminant
validity. However, in trials attempting early
identiﬁcation of high-risk individuals for
interventions (e.g., for enrollment based on
PGD grade within 24 h), it is reasonable to
use the ﬁrst discrete blood gas on arrival to
the intensive care unit (T0) severe PGD
grade to identify high-risk recipients for
early postoperative interventions. This is
justiﬁable because all deﬁnitions were
capable of deﬁning high-risk candidates for
early intervention using the T0 grade, albeit
with some sacriﬁce in discrimination.
The effect of mechanical ventilation
on validity of PGD deﬁnition was minimal.
In addition, there was no interaction between
ventilator status and PGD grade on mortality
discrimination. However, subjects with
severe PGD based on P/F and chest
radiograph at 72 hours who were reclassiﬁed
as a lower PGD grade due to lack of
mechanical ventilation use demonstrated
mortality that was signiﬁcantly higher than
“traditional” no PGD recipients. Therefore,
presence of mechanical ventilation should
be explicitly reported, and should not result
in an empirical change in PGD grading.
Furthermore, it would seem prudent that
regulatory agencies recommend reporting
short-term mortality along with PGD grade.
We also investigated the effects of
transplant type on deﬁnition performance,
given the concern for potential native lung
contribution to P/F ratios in PGD grading.
Transplant procedure type had no
interaction with PGD grade on mortality
discrimination. Furthermore, adequate
discriminant validity was demonstrated for
PGD grading within transplant type. There
is evidence, therefore, to support reporting
PGD grades in aggregate based on
transplant type; however, adjuncts reporting
within individual transplant type should be
considered, or care should be taken to
ensure balanced distribution of transplant
type between comparator groups.
There are several potential limitations
of this study. There is the potential for
misclassiﬁcation of PGD due to missing or
incorrect data. Because data were collected
prospectively, audited regularly, and are
missing in less than 0.5% of the variables of
interest, misclassiﬁcation is less likely. The use
of extracorporeal membrane oxygenation,
inhaled vasodilator medicines, and noninvasive
ventilation in this cohort was limited to very
small numbers of patients (,20), preventing
any substantive evaluation of effects on grading
and mortality. Given that practice patterns
have changed during the period of our study,
future studies of the effects of extracorporeal
membrane oxygenation, pulmonary
vasodilators, and noninvasive ventilation
strategies are warranted, particularly as these
strategies have become more frequently used
in recent years. The LTOG dataset did not
include endpoints assessing chronic lung
allograft dysfunction, which has been shown to
be associated with PGD in prior studies
(38–40). Given the relationship of lower PGD
grades with chronic lung allograft dysfunction
in these prior studies, future investigation is
warranted. Though deﬁnition performance
with a lung injury biomarker previously shown
to be associated with binary PGD deﬁnitions
was excellent, other biomarkers may not also
demonstrate a dose–response effect based on
degree of lung injury. Additional work will be
needed to evaluate other identiﬁed biomarkers
in separate populations. The generalizability of
these results to non-LTOG sites has not been
proven; however, this cohort is speciﬁcally
designed to study PGD, and includes
transplant recipients from 10 U.S. centers of
varying size and location; therefore, it provides
the largest sample size for study of PGD
currently available.
In summary, we have demonstrated
construct validity of the ISHLT deﬁnition,
regardless of presence of mechanical
ventilation and procedure type. Combining
grading categories with P/F greater than 300
is justiﬁed in most circumstances, and
grading at later time points provides the most
impactful clinical deﬁnition for PGD risk or
prevention studies. Further addition of PGD
severity categories below P/F ratios of 200
had minimal to no effects on mortality or
biomarker discrimination, except when
graded at the earliest time points. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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Figure 4. Kaplan-Meier survival of International Society for Heart and Lung Transplantation (ISHLT)
definition after adjustment for mechanical ventilation status. Demonstrated are comparisons of the
ISHLT definition for the 72-hour discrete time point. Significance was determined by the log-rank test.
Curves are discriminated by color: blue, no primary graft dysfunction (PGD); green, severe PGD
reclassified as no PGD owing to absence of mechanical ventilation status; and red, severe PGD.
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